Stock Track | DIAGENS-B Soars 9.34% Intraday on Stellar 2025 Results and 331.7% Surge in Tech Licensing Revenue

Stock Track05-13

DIAGENS-B's stock price soared 9.34% during the late trading session, following the release of the company's impressive 2025 annual performance report.

The surge is attributed to the company's outstanding financial results, which showed annual total revenue skyrocketing 133.7% year-on-year to RMB 164 million. A key driver was the technology licensing business, whose revenue exploded by 331.7% to RMB 84.34 million, becoming the company's largest income source for the first time with a gross profit margin nearing 87.3%.

This dramatic growth in its core licensing segment is seen as a powerful validation of the commercial closed-loop for its medical AI large model. The endorsement of its iMedImage® foundational model by leading institutions further solidifies its strategic position as a global AI medical infrastructure service provider, fueling investor confidence.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1115074411?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 15:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115074411","market":"sg","top_or_hot":-1,"title":"Stock Track | DIAGENS-B Soars 9.34% Intraday on Stellar 2025 Results and 331.7% Surge in Tech Licensing Revenue","media":"Stock Track","content":"<p>DIAGENS-B's stock price soared 9.34% during the late trading session, following the release of the company's impressive 2025 annual performance report.</p><p>The surge is attributed to the company's outstanding financial results, which showed annual total revenue skyrocketing 133.7% year-on-year to RMB 164 million. A key driver was the technology licensing business, whose revenue exploded by 331.7% to RMB 84.34 million, becoming the company's largest income source for the first time with a gross profit margin nearing 87.3%.</p><p>This dramatic growth in its core licensing segment is seen as a powerful validation of the commercial closed-loop for its medical AI large model. The endorsement of its iMedImage® foundational model by leading institutions further solidifies its strategic position as a global AI medical infrastructure service provider, fueling investor confidence.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | DIAGENS-B Soars 9.34% Intraday on Stellar 2025 Results and 331.7% Surge in Tech Licensing Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | DIAGENS-B Soars 9.34% Intraday on Stellar 2025 Results and 331.7% Surge in Tech Licensing Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-13 15:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>DIAGENS-B's stock price soared 9.34% during the late trading session, following the release of the company's impressive 2025 annual performance report.</p><p>The surge is attributed to the company's outstanding financial results, which showed annual total revenue skyrocketing 133.7% year-on-year to RMB 164 million. A key driver was the technology licensing business, whose revenue exploded by 331.7% to RMB 84.34 million, becoming the company's largest income source for the first time with a gross profit margin nearing 87.3%.</p><p>This dramatic growth in its core licensing segment is seen as a powerful validation of the commercial closed-loop for its medical AI large model. The endorsement of its iMedImage® foundational model by leading institutions further solidifies its strategic position as a global AI medical infrastructure service provider, fueling investor confidence.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02526","symbol_name":"德适-B","start_time":0,"source_url":"","article_id":"1115074411","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115074411","pubTimestamp":1778657369,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"DIAGENS-B's stock price soared 9.34% during the late trading session, following the release of the company's impressive 2025 annual performance report.The surge is attributed to the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02526":"德适-B"},"translate_title":"个股追踪|DIAGENS-B盘中飙升9.34%，2025年业绩亮眼，技术授权收入激增331.7%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02526":1},"content_text":"DIAGENS-B's stock price soared 9.34% during the late trading session, following the release of the company's impressive 2025 annual performance report.The surge is attributed to the company's outstanding financial results, which showed annual total revenue skyrocketing 133.7% year-on-year to RMB 164 million. A key driver was the technology licensing business, whose revenue exploded by 331.7% to RMB 84.34 million, becoming the company's largest income source for the first time with a gross profit margin nearing 87.3%.This dramatic growth in its core licensing segment is seen as a powerful validation of the commercial closed-loop for its medical AI large model. The endorsement of its iMedImage® foundational model by leading institutions further solidifies its strategic position as a global AI medical infrastructure service provider, fueling investor confidence.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1115074411","isCrawlerRequest":true}